Wegovy 6 Month Results: What the Evidence Actually Shows

The myth: six months is when Wegovy delivers its full result

The most common misconception about Wegovy at the six-month mark is that results should be peaking or complete. They are not. The dose schedule for semaglutide injection starts at 0.25mg and moves through 0.5mg, 1.0mg and 1.7mg before reaching the 2.4mg maintenance dose, with roughly four weeks at each level. That means many people are still in the titration phase at month six, or have only recently arrived at 2.4mg. The body's full response to the maintenance dose takes additional weeks to manifest. Expecting peak results at six months is a bit like judging a loaf of bread halfway through baking.

The STEP 1 trial (1,961 adults, no diabetes, 68 weeks) reported an average weight reduction of approximately 15% at the full endpoint. At six months, the curve was still climbing. Participants who had reached 2.4mg by that point were showing meaningful progress, but the steepest continued losses came in the months that followed. So if you are at month six and feel results are slower than expected, the timeline itself may simply be the explanation.

For a broader sense of how the trajectory builds from early on, the three-month results picture gives useful context for the first half of treatment.

What the evidence suggests is realistic at six months

Precise six-month figures were not the primary endpoint of STEP 1, so interpreting them requires care. Based on the trial's published weight-loss curves, a reasonable expectation for someone who started on time and tolerated titration well is somewhere in the region of 8–12% average body-weight reduction by month six, though individual variation is wide. Some people see more; some see less. Starting weight, how quickly doses were increased, side-effect history and lifestyle factors all play a role.

What does 10% mean in practice? For someone starting at 95kg, that is roughly 9–10kg. For someone starting at 120kg, closer to 12kg. The numbers are significant, but they are also a waypoint. The full timeline for how Wegovy works makes clear that the medicine's effect compounds over time rather than arriving in a single burst.

NICE's appraisal of semaglutide (Wegovy) notes that treatment should be reviewed if less than 5% weight loss has occurred after six months at the maintenance dose, per NICE technology appraisal TA875. That threshold is a clinical checkpoint, not a prediction of failure, the vast majority of people on the maintenance dose will have cleared it comfortably by this point.

Why individual results diverge so much by month six

A question our prescribers hear regularly: "I'm doing everything right, why is my friend losing more than me?" Several factors create genuine variation that has nothing to do with effort. How quickly the dose was increased matters enormously. Someone who tolerated each step well and reached 2.4mg by week 16 has had more time at the therapeutic dose than someone who needed to pause at 1.0mg for an extra month due to nausea. Both responses are clinically appropriate; the results at six months will simply differ.

Baseline characteristics matter too. People with a higher starting BMI often see larger absolute losses early on. Muscle mass, sleep quality, stress levels and dietary changes alongside treatment all influence the outcome. One practical detail that affects consistency: keeping the pen stored correctly in the fridge door and injecting on the same day each week, small habits that protect the medicine's effectiveness over a course that runs for well over a year.

If you are comparing your six-month progress to trial averages, remember that trial participants had structured lifestyle support throughout. Real-world results are spread across a wider range, and reading about what people typically experience in the first month of Wegovy can help illustrate just how differently the journey begins for each person. The month five results page explores some of these mid-treatment dynamics in more detail.

What to do if you are at six months and uncertain about progress

Six months is a sensible time to take stock, but the right person to do that with is your prescriber, not a forum. A clinical review at this point can assess whether your dose is optimal, whether any side effects are affecting adherence, and whether the trajectory is on track for your individual starting point. Those who want to understand how progress tends to look partway through treatment may find it helpful to read about what Wegovy typically achieves by the four-month point, as it puts the six-month picture in clearer perspective. Stopping Wegovy abruptly at six months because progress feels slow would mean missing the phase where, for many people, results are still accelerating.

It is also worth understanding the broader picture of what Wegovy is and is not licensed to do. The Wegovy treatment overview covers eligibility, how it is prescribed in the UK and what the licence covers, useful reading before drawing conclusions from month-six data alone.

At nume, every repeat prescription involves a clinical review by a GPhC-registered prescriber, not an automated system. If month six raises questions, that review is the place to raise them. To explore whether Wegovy is clinically suitable for you, speak to our prescribers through a free consultation, the process is straightforward, the assessment is thorough, and there is no obligation.